title: Enhancement of the oral bioavailability of phenytoin by N-acetylation and absorptive characteristics.
abstract: To improve the absorbability of phenytoin (DPH), a prodrug, N-acetyl-DPH (EDPH), was synthesized, and the absorptive characteristics and pharmacokinetics of the prodrug were evaluated in rats. EDPH was rapidly hydrolyzed to DPH in the intestinal fluid and the mucosa (rate constant, 0.055 and 0.169 min(-1), respectively). The plasma concentrations of DPH after intravenous dosing of EDPH declined in a biexponential manner, although two different elimination patterns were observed in these rats. When dosed orally (25 mg/kg, DPH equivalent), the plasma levels of DPH converted from the prodrug were significantly higher and more sustained than those after DPH alone, giving bioavailability 11.4 (rapid decay) and 9.1 times (slow decay) as high, respectively, as that after DPH alone. The concentrations of DPH distributed into the mucosa of the duodenum and jejunum 1 and 5 h after oral dosing of EDPH were significantly higher than those after DPH alone. The prodrug and DPH converted from the prodrug dissolved 2-4 fold more than DPH alone in bile salt solution and bile salt-oleic acid mixed micelles, indicating the increased solubility of the prodrug in the intestinal fluid. It is concluded from the data that such high solubility of EDPH enhanced the intestinal absorption of the prodrug, part of which would be absorbed in the amide form, and thus gave the high bioavailability.
authors.affiliation: Faculty of Pharmaceutical Sciences, Kinki University, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ogiso
authors.forename: T
authors.initials: T
authors.lastname: Tanino
authors.forename: D
authors.initials: D
authors.lastname: Kawaratani
authors.forename: M
authors.initials: M
authors.lastname: Iwaki
authors.forename: G
authors.initials: G
authors.lastname: Tanabe
authors.forename: O
authors.initials: O
authors.lastname: Muraoka
mesh_terms: D000107:Acetylation; D000284:Administration, Oral; D000818:Animals; D001647:Bile Acids and Salts / Q000737:chemistry; D001682:Biological Availability; D002021:Buffers; D006868:Hydrolysis; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D008823:Micelles; D010672:Phenytoin / Q000031:analogs & derivatives* / Q000097:blood / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology; D011355:Prodrugs / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D014018:Tissue Distribution; D014867:Water / Q000737:chemistry
chemical_list: D001647:Bile Acids and Salts; D002021:Buffers; D008823:Micelles; C116426:N-acetylphenytoin; D011355:Prodrugs; D014867:Water; C041562:1-acetyl-3-acetoxy-5',5-diphenylhydantoin; D010672:Phenytoin